Tvardi Therapeutics (TVRD) EPS (Basic): 2013-2017
Historic EPS (Basic) for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to -$0.38.
- Tvardi Therapeutics' EPS (Basic) rose 9.52% to -$0.38 in Q3 2017 from the same period last year, while for Sep 2017 it was -$2.29, marking a year-over-year decrease of 39.63%. This contributed to the annual value of -$2.10 for FY2016, which is 110.00% down from last year.
- Latest data reveals that Tvardi Therapeutics reported EPS (Basic) of -$0.38 as of Q3 2017, which was down 31.03% from -$0.29 recorded in Q2 2017.
- Over the past 5 years, Tvardi Therapeutics' EPS (Basic) peaked at -$0.10 during Q2 2013, and registered a low of -$1.07 during Q3 2013.
- Its 3-year average for EPS (Basic) is -$0.42, with a median of -$0.38 in 2017.
- Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 72.90% in 2014, then tumbled by 131.43% in 2016.
- Quarterly analysis of 5 years shows Tvardi Therapeutics' EPS (Basic) stood at -$0.49 in 2013, then surged by 63.27% to -$0.18 in 2014, then tumbled by 94.44% to -$0.35 in 2015, then tumbled by 131.43% to -$0.81 in 2016, then climbed by 9.52% to -$0.38 in 2017.
- Its last three reported values are -$0.38 in Q3 2017, -$0.29 for Q2 2017, and -$0.81 during Q1 2017.